Christina Louise Rasmussen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Christina Louise Rasmussen has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Susanne Kriiger Kjaer
Unit of Virus, Lifestyle and Genes Danish Cancer Institute Copenhagen Denmark
6 shared publications - Freija Verdoodt
Belgian Cancer Registry, 1210 Brussels, Belgium
3 shared publications - Freja Lærke Sand
Unit of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark
3 shared publications - Louise Thirstrup Thomsen
Unit of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark
3 shared publications - Aivara Urbute
Unit of Virus, Lifestyle, and Genes, Danish Cancer Society Research Centre, Copenhagen, Denmark
2 shared publications - Hanna Kristina Bertoli
Unit of Virus, Lifestyle, and Genes Danish Cancer Society Research Center Copenhagen Denmark
2 shared publications
Latest Publications
- Open Access
- 24 June 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (9) , 4812-4824
PIONEER REAL Spain : A multicentre, prospective, real‐world study of oral semaglutide use in adults with type 2 diabetes
Aims: This study evaluated clinical outcomes of oral semaglutide treatment in adults with type 2 diabetes (T2D) in a real‐world setting in Spain as part of the 13‐country PIONEER REAL programme. Materials and Methods: This multicentre, prospective, non‐interventional, single‐arm study (NCT05443334) followed participants for 34–44 weeks. Participants were treated as part of routine clinical practice and were naïve to injectable glucose‐lowering medication. The primary endpoint was the change in glycated haemoglobin (HbA 1c ) from baseline to end of study (EOS). Secondary endpoints included changes in body weight, the proportion of participants with HbA 1c 1c was −1.4%‐points (95%CI −1.5, −1.3; p < 0.0001) and in body weight −6.8% (95%CI −7.4, −6.1; p < 0.0001). In participants using SGLT2is, change in HbA 1c was −1.8%‐points (95%CI −2.1, −1.6; p < 0.0001) versus −1.2%‐points (95%CI −1.3, −1.1; p < 0.0001) in participants without SGLT2is. HbA 1c change was −1.4%‐points (95%CI −1.6, −1.3; p < 0.0001) in participants with T2D duration ≤5 years versus −1.2%‐points (95%CI −1.3, −1.0; p < 0.0001) with T2D duration >5 years. At EOS, 77.4% of participants achieved an HbA 1c level 1c and ≥5% body weight reduction. Treatment satisfaction increased, and no new safety concerns were identified. Conclusions: Oral semaglutide treatment improved glycaemic control and reduced body weight in Spanish clinical practice. Early intervention and SGLT2i co‐treatment were associated with more favourable outcomes.
- 24 June 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (9) , 4812-4824
Open AccessPIONEER REAL Spain : A multicentre, prospective, real‐world study of oral semaglutide use in adults with type 2 diabetes
Aims: This study evaluated clinical outcomes of oral semaglutide treatment in adults with type 2 diabetes (T2D) in a real‐world setting in Spain as part of the 13‐country PIONEER REAL programme. Materials and Methods: This multicentre, prospective, non‐interventional, single‐arm study (NCT05443334) followed participants for 34–44 weeks. Participants were treated as part of routine clinical practice and were naïve to injectable glucose‐lowering medication. The primary endpoint was the change in glycated haemoglobin (HbA 1c ) from baseline to end of study (EOS). Secondary endpoints included changes in body weight, the proportion of participants with HbA 1c 1c was −1.4%‐points (95%CI −1.5, −1.3; p < 0.0001) and in body weight −6.8% (95%CI −7.4, −6.1; p < 0.0001). In participants using SGLT2is, change in HbA 1c was −1.8%‐points (95%CI −2.1, −1.6; p < 0.0001) versus −1.2%‐points (95%CI −1.3, −1.1; p < 0.0001) in participants without SGLT2is. HbA 1c change was −1.4%‐points (95%CI −1.6, −1.3; p < 0.0001) in participants with T2D duration ≤5 years versus −1.2%‐points (95%CI −1.3, −1.0; p < 0.0001) with T2D duration >5 years. At EOS, 77.4% of participants achieved an HbA 1c level 1c and ≥5% body weight reduction. Treatment satisfaction increased, and no new safety concerns were identified. Conclusions: Oral semaglutide treatment improved glycaemic control and reduced body weight in Spanish clinical practice. Early intervention and SGLT2i co‐treatment were associated with more favourable outcomes.
- Open Access
- 1 February 2023
- Published by Wiley in International Journal of Cancer
- Vol. 152 (11) , 2424-2432
Time trends in prevalence of p16 positivity and combined HPV/p16 positivity in a large cohort of Danish vulvar cancer patients
Vulvar cancer is rare, but causes substantial morbidity in affected patients. A subset of vulvar cancers is caused by high‐risk human papillomavirus (hrHPV), which primarily exerts its oncogenic effect through upregulation of tumor suppressor protein p16. Tumors positive for both hrHPV and p16 (double positive) are assumed to be HPV‐driven, but only few large studies have investigated the combined prevalence of hrHPV and p16 positivity in vulvar cancer over time. In this Danish cross‐sectional study, we assessed the prevalence of p16 positivity and double positivity for hrHPV and p16 in a large sample of vulvar squamous cell carcinomas (VSCCs) diagnosed during 1990 to 2017. In a nationwide register, we identified VSCCs from 13 hospitals across Denmark, and collected archival tumor tissue for hrHPV testing with INNO‐LiPA and immunohistochemical p16 staining. We calculated the prevalence of hrHPV, p16 positivity and double positivity according to time, age and histological subtype and evaluated time trends through estimated annual percentage changes. We included 1278 VSCCs. Overall, 35.0% (95% confidence interval [CI]: 32.4‐37.6) were positive for p16 and 31.0% (95% CI: 28.4‐33.5) were positive for both hrHPV and p16. The prevalence of p16 positivity and double positivity increased over time, both in women aged ≤59 and ≥60 years. The double positive prevalence was higher in nonkeratinizing (60.7%) and warty/basaloid VSCCs (67.5%) than in keratinizing (16.1%) and verrucous VSCCs (5.0%). These results indicate that approximately one‐third of vulvar cancers were caused by hrHPV infection, supporting a substantial preventive potential of the HPV vaccine.
- 1 February 2023
- Published by Wiley in International Journal of Cancer
- Vol. 152 (11) , 2424-2432
Open AccessTime trends in prevalence of p16 positivity and combined HPV/p16 positivity in a large cohort of Danish vulvar cancer patients
Vulvar cancer is rare, but causes substantial morbidity in affected patients. A subset of vulvar cancers is caused by high‐risk human papillomavirus (hrHPV), which primarily exerts its oncogenic effect through upregulation of tumor suppressor protein p16. Tumors positive for both hrHPV and p16 (double positive) are assumed to be HPV‐driven, but only few large studies have investigated the combined prevalence of hrHPV and p16 positivity in vulvar cancer over time. In this Danish cross‐sectional study, we assessed the prevalence of p16 positivity and double positivity for hrHPV and p16 in a large sample of vulvar squamous cell carcinomas (VSCCs) diagnosed during 1990 to 2017. In a nationwide register, we identified VSCCs from 13 hospitals across Denmark, and collected archival tumor tissue for hrHPV testing with INNO‐LiPA and immunohistochemical p16 staining. We calculated the prevalence of hrHPV, p16 positivity and double positivity according to time, age and histological subtype and evaluated time trends through estimated annual percentage changes. We included 1278 VSCCs. Overall, 35.0% (95% confidence interval [CI]: 32.4‐37.6) were positive for p16 and 31.0% (95% CI: 28.4‐33.5) were positive for both hrHPV and p16. The prevalence of p16 positivity and double positivity increased over time, both in women aged ≤59 and ≥60 years. The double positive prevalence was higher in nonkeratinizing (60.7%) and warty/basaloid VSCCs (67.5%) than in keratinizing (16.1%) and verrucous VSCCs (5.0%). These results indicate that approximately one‐third of vulvar cancers were caused by hrHPV infection, supporting a substantial preventive potential of the HPV vaccine.
- 1 November 2021
- Published by Elsevier in European Journal of Cancer
- Vol. 157, 165-178
Prognostic value of high-risk human papillomavirus DNA and p16INK4a immunohistochemistry in patients with anal cancer: An individual patient data meta-analysis
- 1 November 2021
- Published by Elsevier in European Journal of Cancer
- Vol. 157, 165-178
Prognostic value of high-risk human papillomavirus DNA and p16INK4a immunohistochemistry in patients with anal cancer: An individual patient data meta-analysis
- Open Access
- 21 September 2021
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 100 (12) , 2144-2156
The prognostic significance of HPV, p16, and p53 protein expression in vaginal cancer: A systematic review
Introduction: Human papillomavirus (HPV), p16, and p53 have been investigated as prognostic markers in various HPV‐related cancers. Within the field of vaginal cancer, however, the evidence remains sparse. In this systematic review, we have compiled the presently published studies on the prognostic significance of HPV and immunohistochemical expression of p16 and p53 among women with vaginal cancer.Material and methods: We conducted a systematic search of PubMed, Embase, and Cochrane Library to identify relevant studies published until April 2021. We included studies reporting survival after histologically verified vaginal cancers tested for HPV, p16, and/or p53. Survival outcomes included overall survival, disease‐free survival, disease‐specific survival, and progression‐free survival.Results: We included a total of 12 studies. The vast majority of vaginal cancer cases included in each study were squamous cell carcinomas (84%–100%). Seven studies reported survival after vaginal cancer according to HPV status, and the majority of these studies found a tendency towards improved survival for women with HPV‐positive vaginal cancer. Three out of four studies reporting survival according to p16 status found an improved survival among women with p16‐positive vaginal cancer. For p53, only one of six studies reported an association between p53 expression and survival.Conclusions: This systematic review suggests that women with HPV‐ and p16‐positive vaginal cancer have an improved prognosis compared with those with HPV‐ or p16‐negative vaginal cancer. Results for p53 were varied, and no conclusion could be reached. Only 12 studies could be included in the review, of which most were based on small populations. Hence, further and larger studies on the prognostic impact of HPV, p16, and p53 in vaginal cancer are warranted.
- 21 September 2021
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 100 (12) , 2144-2156
Open AccessThe prognostic significance of HPV, p16, and p53 protein expression in vaginal cancer: A systematic review
Introduction: Human papillomavirus (HPV), p16, and p53 have been investigated as prognostic markers in various HPV‐related cancers. Within the field of vaginal cancer, however, the evidence remains sparse. In this systematic review, we have compiled the presently published studies on the prognostic significance of HPV and immunohistochemical expression of p16 and p53 among women with vaginal cancer.Material and methods: We conducted a systematic search of PubMed, Embase, and Cochrane Library to identify relevant studies published until April 2021. We included studies reporting survival after histologically verified vaginal cancers tested for HPV, p16, and/or p53. Survival outcomes included overall survival, disease‐free survival, disease‐specific survival, and progression‐free survival.Results: We included a total of 12 studies. The vast majority of vaginal cancer cases included in each study were squamous cell carcinomas (84%–100%). Seven studies reported survival after vaginal cancer according to HPV status, and the majority of these studies found a tendency towards improved survival for women with HPV‐positive vaginal cancer. Three out of four studies reporting survival according to p16 status found an improved survival among women with p16‐positive vaginal cancer. For p53, only one of six studies reported an association between p53 expression and survival.Conclusions: This systematic review suggests that women with HPV‐ and p16‐positive vaginal cancer have an improved prognosis compared with those with HPV‐ or p16‐negative vaginal cancer. Results for p53 were varied, and no conclusion could be reached. Only 12 studies could be included in the review, of which most were based on small populations. Hence, further and larger studies on the prognostic impact of HPV, p16, and p53 in vaginal cancer are warranted.
- 1 June 2020
- Published by Elsevier in Gynecologic Oncology
- Vol. 157 (3) , 664-670
Incidence of vulvar high-grade precancerous lesions and cancer in Denmark before and after introduction of HPV vaccination
- 1 June 2020
- Published by Elsevier in Gynecologic Oncology
- Vol. 157 (3) , 664-670
Incidence of vulvar high-grade precancerous lesions and cancer in Denmark before and after introduction of HPV vaccination
- 1 April 2020
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 29 (4) , 703-710
Prognostic Significance of HPV DNA and p16INK4a in Anal Cancer: A Systematic Review and Meta-Analysis
We conducted a systematic review and meta-analysis of observational studies evaluating survival in patients with anal cancer, according to human papillomavirus (HPV) DNA, p16INK4a, and combined HPV DNA/p16INK4a status. We systematically searched PubMed, EMBASE, and Cochrane Library databases to identify studies published in English until July 25, 2018, directly providing or allowing estimation of survival of patients with anal cancer according to the presence of HPV DNA and/or overexpression of p16INK4a. We estimated pooled HRs and 95% confidence intervals (CI) for overall survival (OS) using a random-effects model. We included 16 studies, comprising 1,724 patients with anal cancer tested for HPV DNA (65% positive), and 567 patients tested for p16INK4a (87% positive). The pooled HR for OS was 0.54 (95% CI, 0.33–0.89) for HPV DNA positive versus negative, 0.37 (95% CI, 0.24–0.57) for p16INK4a positive versus negative, and 0.36 (95% CI, 0.22–0.58) for HPV DNA positive/p16INK4a positive versus HPV DNA positive/p16INK4a negative patients with anal cancer. Patients with HPV DNA or p16INK4a positive anal cancer have significantly better OS compared with HPV DNA or p16INK4a negative. This points to the possible value of HPV DNA and/or p16INK4a testing when planning the management and follow-up strategy for patients diagnosed with anal cancer.
- 1 April 2020
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 29 (4) , 703-710
Prognostic Significance of HPV DNA and p16INK4a in Anal Cancer: A Systematic Review and Meta-Analysis
We conducted a systematic review and meta-analysis of observational studies evaluating survival in patients with anal cancer, according to human papillomavirus (HPV) DNA, p16INK4a, and combined HPV DNA/p16INK4a status. We systematically searched PubMed, EMBASE, and Cochrane Library databases to identify studies published in English until July 25, 2018, directly providing or allowing estimation of survival of patients with anal cancer according to the presence of HPV DNA and/or overexpression of p16INK4a. We estimated pooled HRs and 95% confidence intervals (CI) for overall survival (OS) using a random-effects model. We included 16 studies, comprising 1,724 patients with anal cancer tested for HPV DNA (65% positive), and 567 patients tested for p16INK4a (87% positive). The pooled HR for OS was 0.54 (95% CI, 0.33–0.89) for HPV DNA positive versus negative, 0.37 (95% CI, 0.24–0.57) for p16INK4a positive versus negative, and 0.36 (95% CI, 0.22–0.58) for HPV DNA positive/p16INK4a positive versus HPV DNA positive/p16INK4a negative patients with anal cancer. Patients with HPV DNA or p16INK4a positive anal cancer have significantly better OS compared with HPV DNA or p16INK4a negative. This points to the possible value of HPV DNA and/or p16INK4a testing when planning the management and follow-up strategy for patients diagnosed with anal cancer.
- 18 December 2018
- Published by Wiley in International Journal of Cancer
- Vol. 145 (1) , 78-86
Human papillomavirus and p16 in squamous cell carcinoma and intraepithelial neoplasia of the vagina
We estimated the overall and type‐specific prevalence of human papillomavirus (HPV) and p16 overexpression in vaginal cancer and vaginal intraepithelial neoplasia (VaIN). We conducted a systematic search of PubMed, Embase and Cochrane Library to identify studies published between 1986 and 2017 using PCR‐based or Hybrid Capture 2 tests to evaluate the presence of HPV DNA and/or using any method to detect p16 overexpression in VaIN, vaginal squamous cell carcinoma (VaSCC), or other types of vaginal cancer. Applying a random effects model, we estimated the pooled prevalence of HPV and p16 overexpression along with 95% confidence intervals (CIs). The I2 statistic was used to assess heterogeneity. We included 26 studies, reporting HPV prevalence and six studies evaluating p16 overexpression. The pooled HPV prevalences in VaSCC (n = 593) and VaIN (n = 1,374) were 66.7% (95% CI = 54.7–77.8) and 85.2% (95% CI = 78.2–91.0), respectively. Substantial inter‐study heterogeneity was observed, and analyses stratified on geographic region, type of tissue, HPV detection method or PCR primer type did not fully explain the observed heterogeneity. The most predominant HPV type among the HPV positive VaSCC and VaIN cases was HPV16, followed by HPV33, and HPV45 (in VaIN) and HPV18, and HPV33 (in VaSCC). In pooled analyses, 89.9% (95% CI = 81.7–94.6) of HPV positive and 38.9% (95% CI = 0.9–90.0) of HPV negative vaginal cancers were positive for p16 overexpression. Our findings suggest that vaccination against HPV might prevent a substantial proportion of vaginal neoplasia and highlight the need for further studies of the possible clinical value of p16 testing in these patients.
- 18 December 2018
- Published by Wiley in International Journal of Cancer
- Vol. 145 (1) , 78-86
Human papillomavirus and p16 in squamous cell carcinoma and intraepithelial neoplasia of the vagina
We estimated the overall and type‐specific prevalence of human papillomavirus (HPV) and p16 overexpression in vaginal cancer and vaginal intraepithelial neoplasia (VaIN). We conducted a systematic search of PubMed, Embase and Cochrane Library to identify studies published between 1986 and 2017 using PCR‐based or Hybrid Capture 2 tests to evaluate the presence of HPV DNA and/or using any method to detect p16 overexpression in VaIN, vaginal squamous cell carcinoma (VaSCC), or other types of vaginal cancer. Applying a random effects model, we estimated the pooled prevalence of HPV and p16 overexpression along with 95% confidence intervals (CIs). The I2 statistic was used to assess heterogeneity. We included 26 studies, reporting HPV prevalence and six studies evaluating p16 overexpression. The pooled HPV prevalences in VaSCC (n = 593) and VaIN (n = 1,374) were 66.7% (95% CI = 54.7–77.8) and 85.2% (95% CI = 78.2–91.0), respectively. Substantial inter‐study heterogeneity was observed, and analyses stratified on geographic region, type of tissue, HPV detection method or PCR primer type did not fully explain the observed heterogeneity. The most predominant HPV type among the HPV positive VaSCC and VaIN cases was HPV16, followed by HPV33, and HPV45 (in VaIN) and HPV18, and HPV33 (in VaSCC). In pooled analyses, 89.9% (95% CI = 81.7–94.6) of HPV positive and 38.9% (95% CI = 0.9–90.0) of HPV negative vaginal cancers were positive for p16 overexpression. Our findings suggest that vaccination against HPV might prevent a substantial proportion of vaginal neoplasia and highlight the need for further studies of the possible clinical value of p16 testing in these patients.
- 16 November 2017
- Published by Wiley in International Journal of Cancer
- Vol. 142 (6) , 1158-1165
Does HPV status influence survival after vulvar cancer?
High‐risk human papillomavirus (HPV) infection is essential in the carcinogenesis of a substantial part of anogenital and oropharyngeal cancers and has additionally been shown to be a possible predictive marker for survival, especially in oropharyngeal cancer. Studies examining the influence of HPV status on survival after vulvar cancer have been conflicting and limited by small study populations. Therefore, the aim of this review and meta‐analysis was to examine whether HPV status influences survival after vulvar cancer, which, to our knowledge, has not been done before. We conducted a systematic search of PubMed, Cochrane Library and Embase to identify studies examining survival after histologically verified and HPV tested vulvar cancer. A total of 18 studies were eligible for inclusion. Study‐specific and pooled HRs of the 5‐year OS and DFS were calculated using a fixed effects model. The I2 statistic was used to describe heterogeneity. The studies included a total of 1,638 women with HPV tested vulvar cancers of which 541 and 1,097 were HPV‐positive and HPV‐negative, respectively. Fifteen studies included only squamous cell carcinomas. We found a pooled HR of 0.61 (95% CI: 0.48–0.77) and 0.75 (95% CI: 0.57–1.00) for 5‐year OS and DFS, respectively. Across study heterogeneity was moderate to high (OS: I2 = 51%; DFS: I2 = 73%). In conclusion, women with HPV‐positive vulvar cancers have a superior survival compared to women with HPV‐negative, which could be of great clinical interest and provides insight into the differences in the natural history of HPV‐positive and negative vulvar cancers.
- 16 November 2017
- Published by Wiley in International Journal of Cancer
- Vol. 142 (6) , 1158-1165
Does HPV status influence survival after vulvar cancer?
High‐risk human papillomavirus (HPV) infection is essential in the carcinogenesis of a substantial part of anogenital and oropharyngeal cancers and has additionally been shown to be a possible predictive marker for survival, especially in oropharyngeal cancer. Studies examining the influence of HPV status on survival after vulvar cancer have been conflicting and limited by small study populations. Therefore, the aim of this review and meta‐analysis was to examine whether HPV status influences survival after vulvar cancer, which, to our knowledge, has not been done before. We conducted a systematic search of PubMed, Cochrane Library and Embase to identify studies examining survival after histologically verified and HPV tested vulvar cancer. A total of 18 studies were eligible for inclusion. Study‐specific and pooled HRs of the 5‐year OS and DFS were calculated using a fixed effects model. The I2 statistic was used to describe heterogeneity. The studies included a total of 1,638 women with HPV tested vulvar cancers of which 541 and 1,097 were HPV‐positive and HPV‐negative, respectively. Fifteen studies included only squamous cell carcinomas. We found a pooled HR of 0.61 (95% CI: 0.48–0.77) and 0.75 (95% CI: 0.57–1.00) for 5‐year OS and DFS, respectively. Across study heterogeneity was moderate to high (OS: I2 = 51%; DFS: I2 = 73%). In conclusion, women with HPV‐positive vulvar cancers have a superior survival compared to women with HPV‐negative, which could be of great clinical interest and provides insight into the differences in the natural history of HPV‐positive and negative vulvar cancers.